Journal of Computer-Aided Molecular Design

, Volume 19, Issue 7, pp 465–481 | Cite as

A recursive-partitioning model for blood–brain barrier permeation

Article

Summary

A series of bagged recursive partitioning models for log(BB) is presented. Using a LGO-CV, three sets of physical property descriptors are evaluated and found to have Q2 values of 0.51 (CPSA), 0.53 (Ro5x) and 0.53 (MOE). Extrapolating these models to Pfizer chemical space is difficult due to P-glycoprotein (P-gp) mediated efflux. Low correlation coefficients for this test set are improved (R2=0.39) when compounds known to be P-gp substrates or statistical extrapolations are removed. The use of simple linear models for specific chemical series is also found to improve the correlation over a limited chemical space.

Keywords

ADME blood–brain barrier CNS in silico QSAR 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Supplementary material

10822_2005_9001_MOESM1_ESM.pdf (218 kb)
Supplementary material

References

  1. 1.
    Young R.C., et al., (1988) J. Med. Chem. 31: 656Google Scholar
  2. 2.
    Abraham M.H., Chadha H., Mitchell R.C., (1994) J. Pharm. Sci. 83: 1257Google Scholar
  3. 3.
    Lombardo F., Blake J.F., Curatolo W.J., (1996) J. Med. Chem. 39: 4750Google Scholar
  4. 4.
    Platts J.A., et al., (2001) Eur. J. Med. Chem. 36: 719Google Scholar
  5. 5.
    Clark D.E., (1999) J. Pharm. Sci. 88: 815Google Scholar
  6. 6.
    Kelder J., et al., (1999) Pharma. Res. 16: 1514Google Scholar
  7. 7.
    Iyer M., et al., (2002) Pharma. Res. 19: 1611Google Scholar
  8. 8.
    Doniger S., Hofmann T., Yeh J., (2002) J. Comp. Bio. 9: 849Google Scholar
  9. 9.
    van de Waterbeemd H., Kansy M., (1992) Chimia. 46: 299Google Scholar
  10. 10.
    Chadha H., Abraham M.H., Mitchell R.C., (1994) Bio. Med. Chem. Lett. 4: 2511Google Scholar
  11. 11.
    Sippl W., (2002) Curr. Med. Chem.: Central Nervous Syst. Agents. 2: 211Google Scholar
  12. 12.
    Atkinson F., et al., (2002) Curr. Med. Chem.: Central Nervous Syst. Agents. 2: 229Google Scholar
  13. 13.
    Penzotti J.E., Landrum G.A., Putta S., (2004) Curr. Opinion Drug Discovery Dev. 7: 49Google Scholar
  14. 14.
    Lipinski, C.A., In Spellmeyer D.C., (Ed.), Annual Reports in Computational Chemistry, Elsevier: Amsterdam, pp. 155–168Google Scholar
  15. 15.
    Norinder U., Sjoberg P., Osterberg T., (1998) J. Pharm. Sci. 87:952Google Scholar
  16. 16.
    Osterber T., Norinder U., (2001) Eur. J. Pharm. Sci. 12: 327Google Scholar
  17. 17.
    Luco J.M., (1999) J. Chem. Inf. Comput. Sci. 39: 396Google Scholar
  18. 18.
    Rose K., Hall L.H., Kier L.B., (2002) J. Chem. Inf. Comput. Sci. 42: 651Google Scholar
  19. 19.
    Ajay G.W., Bemis, Murcko M.A., (1999) J. Med. Chem. 42: 4942Google Scholar
  20. 20.
    Crivori P., et al., (2000) J. Med. Chem. 43: 2204Google Scholar
  21. 21.
    Adenot M., Lahana R., (2004) J. Chem. Inf. Comput. Sci. 44: 239Google Scholar
  22. 22.
    Maclin R., Opitz D., (1999) J. Art. Intelligence Res. 11: 169Google Scholar
  23. 23.
    Stanton D.T., Jurs P., (1990) C., Anal. Chem. 62: 2323Google Scholar
  24. 24.
    Lipinski C.A., et al., (1997) Adv. Drug Del. Rev. 23: 3Google Scholar
  25. 25.
    Labute P., (2000) J. Mol. Graphics Model. 18: 464Google Scholar
  26. 26.
    Cruciani G., et al., (2000) J. Mol. Struct.: THEOCHEM.503: 17Google Scholar
  27. 27.
    Cruciani, G., Pastor, M. and Clementi, S., In: Gundertofte, K. and Jorgensen, F.E., (Eds.), Molecular Modeling and Prediction of Bioactivity, Kluwer Academic/Plenum Publishers: New York, 2000, 73ppGoogle Scholar
  28. 28.
    Maw H.H., Hall L.H., (2000) J. Chem. Inf. Comput. Sci. 40: 1270Google Scholar
  29. 29.
    Kimberly R., Hall L.H., (2002) J. Chem. Inf. Comput. Sci. 42: 651Google Scholar
  30. 30.
    Gasteiger J., Rudolph C., (1990) J. Sadowski, Tetrahedron Comp. Method. 3: 537Google Scholar
  31. 31.
    Hawkins G.D., et al., 2003 AMSOL. University of Minnesota: MinneapolisGoogle Scholar
  32. 32.
    Hawkins G.D., Cramer C.J., Truhlar D.G., (1996) J. Phys. Chem. 100: 19824Google Scholar
  33. 33.
    Chambers C.C., et al., (1996) J. Phys. Chem. 100: 16385Google Scholar
  34. 34.
    Pearlman, R.S., In Valvani S.C. (Ed.), Physical Chemical Properties of Drugs, Marcel Dekker: New York, 1980Google Scholar
  35. 35.
    Andrews P.R., Craik D.J., Martin J.L., (1984) J. Med. Chem. 27: 1648Google Scholar
  36. 36.
    BioByte, CLOGP. 2005, BioByte Corp: Claremont, CAGoogle Scholar
  37. 37.
    Ertle P., Rohde B., Selter P., (2000) J. Med. Chem. 43: 3714Google Scholar
  38. 38.
    Moriguchi I., et al., (1992) Chem. Pharmacol. Bull. 40: 127Google Scholar
  39. 39.
    Chemical Computing Group Inc, C., 2000 Molecular Operating Environment. Chemical Computing Group Inc: MontrealGoogle Scholar
  40. 40.
    Gasteiger J., Marsili M., (1980) Tetrahedron, 36: 3219Google Scholar
  41. 41.
    Kalvass J.C., Maurer T.S., (2002) Biopharma. Drug Disposition, 23: 327Google Scholar
  42. 42.
    Waterbeemd, H.v.d., Smith D.A., Jones B.C., (2001) J. Comp.-Aided Mol. Design. 15: 273Google Scholar
  43. 43.
    Brejc K., et al., (2001) Nature 411: 269Google Scholar
  44. 44.
    Iven H., Feldbusch E., (1983) Naunyn-Schmiedeberg’s Arch Pharmacol. 324: 153Google Scholar
  45. 45.
    Timmermans P.B.M.W.M., Brands A., Van Zwieten A., (1977) Arch. Pharmacol. 300: 217Google Scholar
  46. 46.
    Cvetkovic M., et al., (1999) Drug Metabol. Dispos. 27: 866Google Scholar
  47. 47.
    de Lange E.C.M., et al., (1994) Brain Research, 666: 1Google Scholar
  48. 48.
    Miyagi N., et al., (1986) J. Pharmacobio-Dynamics 9: 704Google Scholar
  49. 49.
    Rizk M., Curro F.A., Abdel-Rahman M.S., (1995) Pharmacol. Commun. 6: 295Google Scholar
  50. 50.
    Bickel M., Gerny R., (1980) J. Pharmacy Pharmacol. 32: 669Google Scholar
  51. 51.
    Dambisya Y.M., Chan K., Wong C.-L., (1992) J. Pharmacy Pharmacol. 44: 687–690Google Scholar
  52. 52.
    Cox D.S., et al., (2001) J. Pharm. Sci. 90: 1540Google Scholar
  53. 53.
    Chou R.C., Levy G., (1981) J. Pharm. Exp. Therapeutics 219: 42Google Scholar
  54. 54.
    Kunsman G.W., Rohrig T.P., (1993) Am. J. Forensic Med. Pathol. 14: 48Google Scholar
  55. 55.
    Yata N., et al., (1990) Pharma. Res. 7: 1019Google Scholar
  56. 56.
    Vajda F.J.E., et al., (1981) Neurology 31: 486Google Scholar
  57. 57.
    Bolo N.R., et al., (2000) Neuropsychopharmacology 23: 428Google Scholar
  58. 58.
    Lefebvre M., et al., (1999) Life Sci. 64: 805Google Scholar
  59. 59.
    Hosseini-Yeganeh M., Mclachlan A.J., (2001) J. Pharm. Sci. 90: 1817Google Scholar
  60. 60.
    Cheng F.C., et al., (2002) J. Chromatography, A. 949: 35Google Scholar
  61. 61.
    Borg N., Stahle L., (1998) Antimicrob. Agents Chemother. 42: 2174Google Scholar
  62. 62.
    Ibrahim S.S., et al., (1996) Antivirial Chem. Chemother. 7: 167Google Scholar
  63. 63.
    Choo E.F., et al., (2000) Drug Metabolism Disposition 28: 655Google Scholar
  64. 64.
    Anderson B.D., et al., (1990) J. Pharm. Exp. Therapeutics 253: 113Google Scholar
  65. 65.
    Glynn S.L., Yazdanian M., (1998) J. Pharm. Sci. 87: 306Google Scholar
  66. 66.
    Bolander H.G., Wahlstrom G., (1984) Neuropharmacology 23: 977Google Scholar
  67. 67.
    Bolander H.G., Wahlstrom G., Norberg L., (1984) Acta. Phar. et. Tox. 54: 33Google Scholar
  68. 68.
    Lin Y.-J., et al., (1973) Chem. Pharmacol. Bull. 21: 2749Google Scholar
  69. 69.
    Arendt R.M., et al., (1987) Psychopharmacology 93: 72Google Scholar
  70. 70.
    Mandema J., Kuck W.M.T., Danhof M., (1992) Br. J. Pharmacol. 105: 164Google Scholar
  71. 71.
    Scavone J.M., et al., (1987) Arzneim.-Forsch. 37: 2Google Scholar
  72. 72.
    Lin J.H., Chen I.-W., Lin T.-H., (1994) J. Pharm. Exp. Therapeutics 271: 1197Google Scholar
  73. 73.
    Baselt R.C., 2002 Disposition of Toxic Drugs and Chemicals in Man, 6 Foster City, CA: Chemical Toxicology InstituteGoogle Scholar
  74. 74.
    Cruickshank J.M., et al., (1980) Clin. Sci. 59: 453sGoogle Scholar
  75. 75.
    Arendt R.M., et al., (1984) Cardiology 71: 307CrossRefGoogle Scholar
  76. 76.
    Matsui K., et al., (1999) Drug Metabol. Disposition 27: 1406Google Scholar
  77. 77.
    Kewitz H., (1997) Drugs Today 33: 265CrossRefGoogle Scholar
  78. 78.
    Kosasa T., et al., (2000) Eur. J. Pharmacol. 389: 173Google Scholar
  79. 79.
    Vezzani A., et al., (1989) J. Pharm. Exp. Therapeutics, 249: 278Google Scholar
  80. 80.
    Kuroda S., et al., (2001) Chem. Pharmacol. Bull. 49: 988Google Scholar
  81. 81.
    Calder J.A.D., Ganellin C.R., (1994) Drug Design Discovery 11: 259Google Scholar
  82. 82.
    Polli J.W., et al., (2003) J. Pharm. Sci. 92: 2082Google Scholar
  83. 83.
    Pong S.F., Huang C.L., (1974) J. Pharm. Sci. 63: 1527Google Scholar
  84. 84.
    Brown E.A., et al., (1986) Br. J. Pharmacol. 87:569Google Scholar
  85. 85.
    Barkai A.I., Suckow R.F., Cooper T.B., (1984) J. Pharm. Exp. Therapeutics. 230: 330Google Scholar
  86. 86.
    Doran A., et al., (2005) Drug Metabol. Disposition 33:165Google Scholar
  87. 87.
    Hirose H., et al., (2001) J. Pharm. Exp. Therapeutics 297:790Google Scholar
  88. 88.
    Schmalzing G., (1977) Drug Metabol. Disposition 5: 104Google Scholar
  89. 89.
    Tsuneizumi T., Babb S.M., Cohen B.M., (1992) Biol. Psychiatr. 32: 817Google Scholar
  90. 90.
    Sunderland T., Cohen B.M., (1987) Psychiatr. Res. 20: 299Google Scholar
  91. 91.
    Hu O.Y.-P., Curry S.H., (1989) Biopharma. Drug Disposition 10: 537Google Scholar
  92. 92.
    Yeleswaram K., et al., (1995) Res. Comm. Mol. Pathology Pharmacol. 89: 27Google Scholar
  93. 93.
    Scales B., Cosgrove M.B., (1970) J. Pharm. Exp. Therapeutics 175: 338Google Scholar
  94. 94.
    Riah O., et al., (1998) Cell. Mol. Neurobiol. 18: 311Google Scholar
  95. 95.
    Ghosheh O.A., et al., (2001) Drug Metabol. Disposition 29: 645Google Scholar
  96. 96.
    Romano C., Goldstein A., Jewell N.P., (1981) Psychopharmacology 74: 310Google Scholar
  97. 97.
    Rowell P.P., Li M.,. (1997) J. Neurochem. 68: 1982CrossRefGoogle Scholar
  98. 98.
    Schroeder D.H., (1983) J. Clin. Psychiatr. 44: 79Google Scholar
  99. 99.
    Kaplan G.B., et al., (1989) J. Pharm. Exp. Therapeutics 248: 1078Google Scholar
  100. 100.
    Wilkinson J.M., Pollard I., (1993) Dev. Brain Res. 75: 193Google Scholar
  101. 101.
    Terasaki T., et al., (1992) Int. J. Pharmaceutics 81: 143Google Scholar
  102. 102.
    Stahle L., (1991) Life Sci. 49: 1835Google Scholar
  103. 103.
    Ramzan I.M., Levy G., (1986) J. Pharm. Exp. Therapeutics 236: 708Google Scholar
  104. 104.
    Ohshima N., et al., (1995) Biol. Pharma. Bull. 18: 70Google Scholar
  105. 105.
    Argent D., D’Mello A.P., (1994) J. Pharm. Exp. Therapeutics 270: 512Google Scholar
  106. 106.
    Okuyama S., Aihara H., (1984) Jpn. J. Pharmacol. 35: 95Google Scholar
  107. 107.
    Van Belle K., et al., (1995) J. Pharm. Exp. Therapeutics 272: 1217Google Scholar
  108. 108.
    Overo K.F., Jorgensen A., Hansen V., (1970) Acta. Phar. et. Tox. 28: 81Google Scholar
  109. 109.
    Yang H., Wang Q., Elmquist W.F., (1996) Pharma. Res. 13: 1570Google Scholar
  110. 110.
    Von Moltke L.L., et al., (2004) Drug Metab. Disposition 32: 800Google Scholar
  111. 111.
    Aravagiri M., Yuwiler A., Marder S.R., (1998) Psychopharmacology 139: 356Google Scholar
  112. 112.
    Yang Z., et al., (1997) Pharma. Res. 14: 865Google Scholar
  113. 113.
    McNally W., et al., (1989) Pharma. Res. 6: 924Google Scholar
  114. 114.
    Pan W.-J., Hedaya M.A., (1999) J. Pharm. Sci. 88: 468Google Scholar
  115. 115.
    Brogden, R.N., et al., Drugs, 24 (1982) 360Google Scholar
  116. 116.
    Lobell M., Molnar L., Keseru G.M., (2002) J. Pharm. Sci. 92: 360Google Scholar
  117. 117.
    Hou T., Xu X., (2002) J. Mol. Model, 8: 337Google Scholar
  118. 118.
    Keseru G.M., Molnar L., (2001) J. Chem. Inf. Comput. Sci. 41: 120Google Scholar
  119. 119.
    Bennet B., et al., (2000) J. Biol. Chem. 275: 20647Google Scholar
  120. 120.
    Shearman M.S., et al., (2000) Biochemistry 39: 8698Google Scholar
  121. 121.
    Jakovljevic V., Banic B., Radunovic A., (1991) Eur. J. Drug. Met. Pharmacokinetics 16:171CrossRefGoogle Scholar
  122. 122.
    Reavill C., et al., (1990) Neuropharmacology 29: 619Google Scholar
  123. 123.
    Pentel P.R., et al., (2000) Pharmacol. Biochem. Behavior 65: 191Google Scholar

Copyright information

© Springer science + business media 2005

Authors and Affiliations

  1. 1.Pfizer Global Research and DevelopmentGrotonUSA

Personalised recommendations